Literature DB >> 21248746

Congenital muscular dystrophy type 1D (MDC1D) due to a large intragenic insertion/deletion, involving intron 10 of the LARGE gene.

Nigel F Clarke1, Svetlana Maugenre, Aurélie Vandebrouck, J Andoni Urtizberea, Tobias Willer, Rachel A Peat, Françoise Gray, Céline Bouchet, Hiroshi Manya, Sandrine Vuillaumier-Barrot, Tamao Endo, Eliane Chouery, Kevin P Campbell, André Mégarbané, Pascale Guicheney.   

Abstract

Mutation of the LARGE gene is the rarest of the six known genetic causes of α-dystroglycanopathy. We report further a family with MDC1D due to a complex genomic rearrangement that was not apparent on standard sequencing of LARGE. Two sisters in a consanguineous family had moderate mental retardation and cerebellar malformations, together with dystrophic changes and markedly reduced α-dystroglycan glycosylation staining on muscle biopsy. There was homozygous linkage to the LARGE locus but sequencing of LARGE coding regions was normal. Analysis of LARGE cDNA showed an abnormal sequence inserted between exons 10 and 11, in most of the transcripts, predicted to introduce a premature stop codon. The abnormal sequence mapped to a spliced EST (DA935254) of unknown function, normally located at 100 kb centromeric of LARGE on chromosome 22q12.3. Quantitative PCR analysis of the EST and adjacent regions showed twice the normal copy number in patients' genomic DNA samples, consistent with a large intra-chromosomal duplication inserted into intron 10 of LARGE in a homozygous state. This insertion was associated with deletion of a central region of intron 10, but the exact break points of the deletion/duplication were not found, suggesting that an even more complex rearrangement may have occurred. The exact function of LARGE, a golgi protein, remains uncertain. POMT and POMGnT enzyme activities were normal in patients' lymphoblast cells, suggesting that defects in LARGE do not affect the initiation of O-mannosyl glycans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248746      PMCID: PMC3060325          DOI: 10.1038/ejhg.2010.212

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  18 in total

1.  Ocular abnormalities in Large(myd) and Large(vls) mice, spontaneous models for muscle, eye, and brain diseases.

Authors:  Yongsuk Lee; Shuhei Kameya; Gregory A Cox; Jennifer Hsu; Wanda Hicks; Terry P Maddatu; Richard S Smith; Jürgen K Naggert; Neal S Peachey; Patsy M Nishina
Journal:  Mol Cell Neurosci       Date:  2005-10       Impact factor: 4.314

Review 2.  Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage.

Authors:  Paul T Martin
Journal:  Nat Clin Pract Neurol       Date:  2006-04

3.  Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.

Authors:  Hui Xiong; Kazuhiro Kobayashi; Masaji Tachikawa; Hiroshi Manya; Satoshi Takeda; Tomohiro Chiyonobu; Nobuhiro Fujikake; Fan Wang; Akemi Nishimoto; Glenn E Morris; Yoshitaka Nagai; Motoi Kanagawa; Tamao Endo; Tatsushi Toda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-02       Impact factor: 3.575

4.  Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study.

Authors:  E Mercuri; S Messina; C Bruno; M Mora; E Pegoraro; G P Comi; A D'Amico; C Aiello; R Biancheri; A Berardinelli; P Boffi; D Cassandrini; A Laverda; M Moggio; L Morandi; I Moroni; M Pane; R Pezzani; A Pichiecchio; A Pini; C Minetti; T Mongini; E Mottarelli; E Ricci; A Ruggieri; S Saredi; C Scuderi; A Tessa; A Toscano; G Tortorella; C P Trevisan; C Uggetti; G Vasco; F M Santorelli; E Bertini
Journal:  Neurology       Date:  2009-03-18       Impact factor: 9.910

5.  Phenotypic and pathologic evaluation of the myd mouse. A candidate model for facioscapulohumeral dystrophy.

Authors:  K D Mathews; D Rapisarda; H L Bailey; J C Murray; R L Schelper; R Smith
Journal:  J Neuropathol Exp Neurol       Date:  1995-07       Impact factor: 3.685

6.  O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding.

Authors:  Takako Yoshida-Moriguchi; Liping Yu; Stephanie H Stalnaker; Sarah Davis; Stefan Kunz; Michael Madson; Michael B A Oldstone; Harry Schachter; Lance Wells; Kevin P Campbell
Journal:  Science       Date:  2010-01-01       Impact factor: 47.728

7.  Protein O-mannosyltransferase activities in lymphoblasts from patients with alpha-dystroglycanopathies.

Authors:  Hiroshi Manya; Céline Bouchet; Akiko Yanagisawa; Sandrine Vuillaumier-Barrot; Susana Quijano-Roy; Yasushi Suzuki; Svetlana Maugenre; Pascale Richard; Toshiyuki Inazu; Luciano Merlini; Norma B Romero; France Leturcq; Isabelle Bezier; Haluk Topaloglu; Brigitte Estournet; Nathalie Seta; Tamao Endo; Pascale Guicheney
Journal:  Neuromuscul Disord       Date:  2007-09-14       Impact factor: 4.296

8.  Intragenic deletion in the LARGE gene causes Walker-Warburg syndrome.

Authors:  Jeroen van Reeuwijk; Prabhjit K Grewal; Mustafa A M Salih; Daniel Beltrán-Valero de Bernabé; Jenny M McLaughlan; Caroline B Michielse; Ralf Herrmann; Jane E Hewitt; Alice Steinbrecher; Mohamed Z Seidahmed; Mohamed M Shaheed; Abdullah Abomelha; Han G Brunner; Hans van Bokhoven; Thomas Voit
Journal:  Hum Genet       Date:  2007-04-14       Impact factor: 4.132

9.  Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan.

Authors:  Caroline Godfrey; Emma Clement; Rachael Mein; Martin Brockington; Janine Smith; Beril Talim; Volker Straub; Stephanie Robb; Ros Quinlivan; Lucy Feng; Cecilia Jimenez-Mallebrera; Eugenio Mercuri; Adnan Y Manzur; Maria Kinali; Silvia Torelli; Susan C Brown; Caroline A Sewry; Kate Bushby; Haluk Topaloglu; Kathryn North; Stephen Abbs; Francesco Muntoni
Journal:  Brain       Date:  2007-09-18       Impact factor: 13.501

10.  Ethnically diverse causes of Walker-Warburg syndrome (WWS): FCMD mutations are a more common cause of WWS outside of the Middle East.

Authors:  M Chiara Manzini; Danielle Gleason; Bernard S Chang; R Sean Hill; Brenda J Barry; Jennifer N Partlow; Annapurna Poduri; Sophie Currier; Patricia Galvin-Parton; Lawrence R Shapiro; Karen Schmidt; Jessica G Davis; Lina Basel-Vanagaite; Mohamed Z Seidahmed; Mustafa A M Salih; William B Dobyns; Christopher A Walsh
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

View more
  18 in total

1.  Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.

Authors:  Peng Zhang; Huaiyu Hu
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

2.  A review of the diverse genetic disorders in the Lebanese population: highlighting the urgency for community genetic services.

Authors:  Ghunwa Nakouzi; Khalil Kreidieh; Soha Yazbek
Journal:  J Community Genet       Date:  2014-09-27

3.  22q12.3 microduplication overlapping the LARGE gene as a male-only affected loci responsible for increasing the risk of autism spectrum disorder.

Authors:  Xuan Huang; Yingjun Xie; Qun Fang
Journal:  Biomed Rep       Date:  2017-06-07

4.  LARGE, an intellectual disability-associated protein, regulates AMPA-type glutamate receptor trafficking and memory.

Authors:  Bo Am Seo; Taesup Cho; Daniel Z Lee; Joong-Jae Lee; Boyoung Lee; Seong-Wook Kim; Hee-Sup Shin; Myoung-Goo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-18       Impact factor: 11.205

Review 5.  The genomic landscape of African populations in health and disease.

Authors:  Charles N Rotimi; Amy R Bentley; Ayo P Doumatey; Guanjie Chen; Daniel Shriner; Adebowale Adeyemo
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

6.  POMK mutations disrupt muscle development leading to a spectrum of neuromuscular presentations.

Authors:  Stefania Di Costanzo; Anuradha Balasubramanian; Heather L Pond; Anete Rozkalne; Chiara Pantaleoni; Simona Saredi; Vandana A Gupta; Christine M Sunu; Timothy W Yu; Peter B Kang; Mustafa A Salih; Marina Mora; Emanuela Gussoni; Christopher A Walsh; M Chiara Manzini
Journal:  Hum Mol Genet       Date:  2014-06-11       Impact factor: 6.150

7.  Endogenous glucuronyltransferase activity of LARGE or LARGE2 required for functional modification of α-dystroglycan in cells and tissues.

Authors:  Kei-ichiro Inamori; Tobias Willer; Yuji Hara; David Venzke; Mary E Anderson; Nigel F Clarke; Pascale Guicheney; Carsten G Bönnemann; Steven A Moore; Kevin P Campbell
Journal:  J Biol Chem       Date:  2014-08-19       Impact factor: 5.157

8.  Behavioral Responses in Animal Model of Congenital Muscular Dystrophy 1D.

Authors:  Clarissa M Comim; Aryadnne L Schactae; Jaime A Soares; Letícia Ventura; Viviane Freiberger; Francielle Mina; Diogo Dominguini; Mariz Vainzof; João Quevedo
Journal:  Mol Neurobiol       Date:  2014-12-03       Impact factor: 5.590

9.  Muscular dystrophy-dystroglycanopathy in a family of Labrador retrievers with a LARGE1 mutation.

Authors:  G Diane Shelton; Katie M Minor; Ling T Guo; Steven G Friedenberg; Jonah N Cullen; Jeffrey M Hord; David Venzke; Mary E Anderson; Megan Devereaux; Sally J Prouty; Caryl Handelman; Kevin P Campbell; James R Mickelson
Journal:  Neuromuscul Disord       Date:  2021-07-28       Impact factor: 4.296

10.  Clinical, pathologic, and mutational spectrum of dystroglycanopathy caused by LARGE mutations.

Authors:  Katherine G Meilleur; Kristen Zukosky; Livija Medne; Pierre Fequiere; Nina Powell-Hamilton; Thomas L Winder; Abdulaziz Alsaman; Ayman W El-Hattab; Jahannaz Dastgir; Ying Hu; Sandra Donkervoort; Jeffrey A Golden; Ralph Eagle; Richard Finkel; Mena Scavina; Ian C Hood; Lucy B Rorke-Adams; Carsten G Bönnemann
Journal:  J Neuropathol Exp Neurol       Date:  2014-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.